Shimadzu has recently completed a strategic move to bolster its presence in North America.
Shimadzu Corporation has recently acquired Zef Scientific Inc., a leading provider of maintenance and repair services for liquid chromatographs and liquid chromatograph mass spectrometers for the Pharmaceutical Industry.
Through its U.S. subsidiary, Shimadzu Scientific Instruments, Inc., Shimadzu now holds all shares of ZefSci. This positions the latter as a subsidiary under its umbrella.
The acquisition of ZefSci is testament of Shimadzu’s long term commitment to enhancing its after-sales services for pharma companies in North America. It sees the USA as a region which is set for significant growth in the pharmaceutical industry.
At Aport, we’re already supporting this growth throughout the USA. We’re ready to support more companies and organizations as they increase their discovery, development, activity and reach.
There is an escalating demand for comprehensive after-sales services, particularly in the face of stringent quality control requirements. Shimadzu recognizes the necessity of offering multi-vendor services (MVS). This is an effort to meet the evolving needs of the Pharmaceutical Industry.
The trend in North America includes outsourcing instrument management to MVS providers. This has gained momentum recently. Pharmaceutical firms are seeking efficient solutions for analytical equipment maintenance.
ZefSci now emerges as a key player in this landscape. It is distinguished for its expertise in servicing equipment from various manufacturers.
By incorporating ZefSci into its operations, Shimadzu aims to provide customers with a unified service platform, transcending brand boundaries and simplifying their operational efficiency.
Shimadzu is recognizing North America as a strategic hub for its analytical and measurement business. The Shimadzu Group is looking to capitalize on the region’s growth potential in the Pharmaceutical Industry.
With a newly established R&D Center, Shimadzu is well-positioned to drive innovation with drug development and other activities. They are looking to cater to the needs of thePharmaceutical Industry in the region. Based in the United States, they will also be well positioned to serve Mexico and Central America.
The positioning of the company is crucial, as they will be able to reach right from the Aleutian Islands, all across the great plains, down to the isthmus of Panama and Mexico City, serving hundreds of thousands of square miles of human geography.
With the acquisition of Zef Scientific Inc., Shimadzu is showing its readiness to lead the charge in facilitating international investment and collaboration in North America’s pharmaceutical industry. This will support drug discovery and scientific breakthroughs,
As the pharmaceutical landscape continues to evolve, Shimadzu’s acquisition of ZefSci will lead to enhanced service capabilities and streamlined operations across North America, from the Pacific Ocean coast to the Caribbean sea.
With a focus on delivering unparalleled after-sales support and a comprehensive suite of services, Shimadzu is positioned to play a huge role in the future of the pharmaceutical industry in the region and beyond.
At Aport, we aim to support companies in the industry with their relocation and project management services, and so it is pleasing to see such a significant move take place in North America.
We expect more to follow, and we’ll be ready to support wherever we’re needed.
